HC Wainwright Issues Positive Forecast for Vericel (NASDAQ:VCEL) Stock Price

Vericel (NASDAQ:VCEL) had its price objective boosted by investment analysts at HC Wainwright from $72.00 to $75.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright‘s target price would suggest a potential upside of 44.84% from the stock’s previous close.

A number of other research firms have also weighed in on VCEL. Truist Financial reduced their target price on Vericel from $58.00 to $52.00 and set a “buy” rating on the stock in a research note on Wednesday, October 14th. TD Cowen lifted their target price on Vericel from $55.00 to $58.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Wall Street Zen raised shares of Vericel from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. Weiss Ratings restated a “hold (c)” rating on shares of Vericel in a report on Thursday, October 29th. Finally, Canaccord Genuity Group set a $60.00 price target on shares of Vericel in a research note on Thursday, July 30th. Four equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $58.20.

Vericel Stock Performance

VCEL opened at $51.78 on Friday. The stock has a market cap of $2.65 billion, a price-to-earnings ratio of 110.17 and a beta of 1.08. The stock’s 50 day moving average price is $40.74 and its 200-day moving average price is $38.80. Vericel has a one year low of $28.95 and a one year high of $55.60.

Vericel (NASDAQ:VCEL) last issued its quarterly earnings results on Thursday, November 5th. The biotechnology company reported $0.27 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.21. Vericel had a return on equity of 6.91% and a net margin of 7.91%. The firm had revenue of $85.37 million for the quarter, compared to the consensus estimate of $77.95 million. During the same period in the prior year, the business posted $0.10 earnings per share. The company’s revenue for the quarter was up 26.5% on a year-over-year basis. As a group, analysts predict that Vericel will post 0.54 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. bought a new stake in Vericel during the 2nd quarter valued at $360,023,000. William Blair Investment Management LLC purchased a new stake in shares of Vericel in the 2nd quarter worth $88,662,000. Bank of America Corp DE grew its position in shares of Vericel by 19.7% during the 1st quarter. Bank of America Corp DE now owns 1,098,771 shares of the biotechnology company’s stock worth $35,347,000 after buying an additional 180,761 shares in the last quarter. Dimensional Fund Advisors LP grew its position in shares of Vericel by 3.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 844,755 shares of the biotechnology company’s stock worth $27,173,000 after buying an additional 29,135 shares in the last quarter. Finally, TimesSquare Capital Management LLC bought a new position in shares of Vericel during the 2nd quarter worth $24,463,000.

Key Vericel News

Here are the key news stories impacting Vericel this week:

• Positive Sentiment: Third-quarter revenue rose 26% year over year to $85.4 million, while net income increased 179% to $14.2 million. EPS of $0.27 also beat analyst expectations, as did revenue of $85.4 million versus estimates of about $78 million. Vericel third-quarter results and guidance
• Positive Sentiment: Vericel raised its 2026 revenue guidance to $344 million–$346 million, above the roughly $336 million consensus estimate, and forecast a 28% adjusted EBITDA margin. The higher outlook signals continued business momentum. Vericel raises FY2026 outlook
• Positive Sentiment: Coverage highlighted record sales of MACI, Vericel’s cartilage repair product, as a key driver of results and the raised outlook. Vericel record revenue and raised outlook
• Negative Sentiment: A separate analysis characterized VCEL as potentially overvalued relative to its earnings support. That valuation concern could temper investor enthusiasm after the strong results, although the provided article details do not quantify its valuation case. Vericel valuation analysis

Vericel Company Profile

Vericel Corporation is a commercial-stage biopharmaceutical company focused on developing and marketing advanced cell therapies and regenerative medicine products. The company serves orthopedic and burn-care markets, with an emphasis on treatments that use a patient’s own cells or biologic materials to support tissue repair and healing.

Vericel’s primary orthopedic product is MACI, an autologous cultured chondrocyte implant used to repair symptomatic cartilage defects of the knee in adults.